Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm

https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.076

Full Text:

Abstract

Aim. The study aimed to assess the economic effect of biological therapy with anti-interleukin (IL)-6 drugs: tocilizumab, olokizumab, and levilimab in patients with severe COVID-19 and cytokine storm.

Materials and Methods. An assessment of the economic consequences of severe COVID-19 therapy was carried out using the cost of illness analysis in a model developed in Microsoft Excel 2016 (Microsoft, USA). The direct medical costs of providing care for COVID-19 were taken into account (ICU service, the cost of biological therapy, and the use of glucocorticosteroids (GC)). Data from a prospective, historical controlled CHIC study conducted in the Netherlands were used as a source of efficacy. A mathematical model has been developed for extrapolating the CHIC study results to clinical outcomes (transfer to mechanical ventilation, discharge from ICU, lethal outcome) and forecasting the costs of managing severe patients with COVID-19 in real clinical practice in the Russian Federation.

Results. The reduction in the cost of therapy when the hypothesis of equal efficacy of tocilizumab, olokizumab, and levilimab is accepted by reducing the cost of drug therapy will be 1,251,698.99 rubles per 72 patients when comparing olokizumab with tocilizumab and 939,718.84 rubles per 72 patients when comparing olokizumab with levilimab.

Conclusion. Anti-interleukin (IL)-6 drugs in combination with GC are an effective treatment option for moderate to severe patients with COVID-19 and cytokine storm symptoms. This group of drugs is indicated as the main one for the treatment of this condition.

About the Authors

M. Yu. Frolov
Volgograd State Medical University of the Ministry of Health of the Russian Federation; Volgograd Medical Scientific Center
Russian Federation

Maxim Yu. Frolov - MD, PhD, Associate Professor, Department of Pharmacology and Pharmacy Volgograd SMU; Head of the Laboratory of informatization and digitalization of healthcare Volgograd MRC. Scopus Author ID: 35193977700; WoS Researcher ID: F-8355-2015; RSCI SPIN-code: 7585-1728.

1 pl. Pavshikh Bortsov, Volgograd 400131



A. S. Salasyuk
Volgograd State Medical University of the Ministry of Health of the Russian Federation
Russian Federation

Alla S. Salasyuk - MD, PhD, Associate Professor, Department of Internal Medicine, RSCI SPIN-code: 2651-2916.

1 pl. Pavshikh Bortsov, Volgograd 400131



V. A. Rogov
Volgograd State Medical University of the Ministry of Health of the Russian Federation; Volgograd Medical Scientific Center
Russian Federation

Vladimir A. Rogov - PhD (pharmaceutical sciences) Assistant of Professor of the Department of Management and Economics of Pharmacy, Medical and Pharmaceutical Merchandising Volgograd SMU; Senior Researcher of the Laboratory of informatization and digitalization of healthcare Volgograd MRC.

1 pl. Pavshikh Bortsov, Volgograd 400131



References

1. Andersen K. G. et al. The proximal origin of SARS-CoV-2. Nature medicine. 2020; 26 (4): 450-452. https://doi.org/10.1038/s41591-020-0820-9.

2. Hu B. et al. Characteristics oO SARS-CoV-2 ann COVID--9. Nature Reviews Microbiology. 2020; 1-14. https://doi.org/10.1038/s41579-020-00459-7.

3. Online statistics of the coronavirus Covid-1. in Russian (in Russ) [Electronic resource] URL: https://coronnvirus-monitor.ru/coronnvirus-v-rossii/. Accessed: 10.09.2020.

4. Grinevich V.B., Gubonina I.V., Doshchitsin V.L., Kotovskaya Yu.-., Kravchuk Yu.A., Ped V.I., Sas E.I., Syiov A.-., Tarasov A.-., Tarzimanova A.I., Tkacheva O.N., Trukhan D.I. Management of patients with comorbidity during novel coronavirus (CO-I--19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention. 2020; 19 (4): 2630. (In Russ.) https://doi.oig/10.15829/1728-8800-2020-2630.

5. Violi F. et al. Hypercoagulation and antithrombotic treatment in coronavirus 2019: a new challenge. Thrombosis and haemostasis. 2020; 120 (6): 949. https://doi.oig/10.1055/s-0040-1710317.

6. Wu Z., McGoogan J. M. Characteristics of and important lessons from the coronavirus disease 2019 (CO-I--19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for -Disease Control and Prevention. Jama. 2020; 323: 13. https://doi.oig/10.1001/jnmn.2020.2648.

7. Lazzerini M., Putoto G. CO-I--19 in Italy: momentous decisions and many uncertainties. The Lancet Global Health. 2020; 8 (5): e641-e642. https://doi.oig/10.1016/-2214-109X(20)30110-8.

8. Moore J. B., June C. H. June. Cytokine release syndrome in severe CO-I--19. Science. 2020; 368 (6490): 473-474. https://doi.oig/10.1126/science.nbb8925.

9. Lu S . et al. Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis. Annals of translational medicine. 2020; 8 (10). https://doi.oig/10.21037/ntm-20-3307.

10. Conticini E. et al. COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs Annals of the Rheumatic Diseases. 2020; https://doi.oig/10.1136/nnniheumdis-2020-217681.

11. Kamkin E. G. et al. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Temporary guidelines. Version 9 (10/26/2020). Moscow: Ministry of Health of the Russian Federation (in Russ) [Electronic resource] URL: https://stntic-0.minzdinv.gov.ru/system/nttnchments/nttnches/000/052/548/originnl/MP_COVID-19_%28v.9%29.pdf?1603730062. Accessed: 11.11.2020.

12. Li H. et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. The Lancet. 2020; 395 (10235): 1517-1520. https://doi.org/10.1016/-0140-6736(20)30920-X

13. Cardenas G. et al. Role of Systemic and Nasal Glucocorticoid Treatment in the Regulation of the Inflammatory Response in Patients with Snrs-Cov-2 Infection. Archives of Medical Research. 2020; https://doi.org/10.1016/j.nrcmed.2020.10.014

14. Aziz M., Fatima R., Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. Journal of Medical Virology. 2020. 92 (11): 2283-2285. https://doi.org/10.1002/jmv.25948.

15. Liu B. et al. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? Journal of Autoimmunity. 2020; 111: 102452. https://doi.org/10.1016/j.jnut.2020.102452.

16. An update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia [Electronic resource] URL: https://www.roche.com/medin/relenses/med-cor-2020-07-29.htm. Accessed: 11.11.2020.

17. Guaraldi G. et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatology. 2020; 2 (8): e474-e484. https://doi.org/10.1016/S2665-9913(20)30173-9.

18. Della-Torre E. et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Annals of the rheumatic diseases. 2020; 79: 1277-1285. http://dx.doi.org/10.1136/annrheumdis-2020-218122.

19. Russell B. et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence. Ecancermedicalscience. 2020; 14. http://dx.doi.org/10.3332/ecancer.2020.1022.

20. Caracciolo M. et al. Case Report: Canakinumab for the Treatment of a patient with COVID-19 Acute Respiratory Distress Syndrome. Frontiers in Immunology. 2020; 11: 1942. http://dx.doi.org/10.3389/fimmu.2020.01942.

21. Nasonov E.L., Lila A.M. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes. Rheumatology Science and Practice. 2017; 55 (6): 590-599. (In Russ.)

22. Artlegia (olokizumab). Instructions for the medical use of the medicinal product. LP-006218 State Register of Medicines of the Ministry of Health of the Russian Federation

23. New coronavirus infection (COVID-19): etiology, epidemiology, clinic, diagnosis, treatment and prevention. Moscow. 2020; 71 с. (in Russ)

24. Klypa T.V. et al. Clinical characteristics of patients with COVID-19 admitted to the intensive care unit. predictors of severe course. Klinicheskaya praktika. 2020; 11 (2): 6-20. (in Russ).

25. Manson J. J. et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. The Lancet Rheumatology. 2020; https://doi.org/10.1016/S2665-9913(20)30275-7.

26. Ramiro S. et al. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the chiC study. Annals of the rheumatic diseases. 2020; 79 (9): 1143-1151. http://dx.doi.org/10.1136/annrheumdis-2020-218479.

27. WHO R&D Blueprint. Novel coronavirus, outline of designs for experimental therapeutics, 2020. [Electronic resource] URL: https://apps.who.int/iris/bitstream/handle/10665/330695/WHO-HEO-RDBlue-printnCoV-2020.5-eng.pdf?sequence=1&isAllowed=y. Accessed: 03.12.2020.

28. Kamkin E. G. et al. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Temporary guidelines. Short version. (in Russ) [Electronic resource] URL: https://стопкоронавирус.рф/ai/doc/204/attach/COVID_pocketbook_v6.pdf. Accessed: 03.12.2020.

29. Data on the maximum amount of wholesale markups and the maximum amount of retail markups to prices for vital and essential medicines established in the constituent entities of the Russian Federation (data as of February 10, 2020) (in Russ) [Electronic resource] URL: https://fas.gov.ru/documents/686367. Accessed: 10.02.2020.

30. Nasonov E., Fatenejad S., Korneva E., Krechikova D., Maslyansky A., Plaksina T., Stanislav M., Stoilov R., Tyabut T., Yakushin S., Zonova E., Genovese M.C. Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active, Rheumatoid Arthritis Inadequately Controlled by Methotrexate - CREDO1 Study [abstract]. Arthritis Rheumatol. 2019; 71 (10). (in Russ).

31. Nasonov E., Stoilov R., Tyabut T., Genovese M.C. Olokizumab, Monoclonal Antibody Against IL6, in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate: Efficacy and Safety Results of Phase III CREDO-1 Study. EU-LAR2020, abstract book, OP0021.

32. Pharmacoeconomics for universities: textbook. allowance / R. I. Yagudina, A. Yu. Kulikov, V. G. Serpik. Rostov-on-Don. 2017; 237. (in Russ).

33. Federal State Statistics Service. Gross domestic product, annual data (in Russ) [Electronic resource] URL: https://www.gks.ru/storage/mediabank/tab1(2).htm. Дата обращения: 10.02.2020.

34. Federal State Statistics Service. The number of resident population on average per year (in Russ) [Электронный ресурс] URL: https://showdata.gks.ru/report/278930/. Дата обращения: 10.02.2020.


For citation:


Frolov M.Yu., Salasyuk A.S., Rogov V.A. Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2020;13(4):377-387. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.076

Views: 551


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)